Arcutis Biotherapeutics, Inc. (ARQT)
23.78
-1.09
(-4.38%)
USD |
NASDAQ |
Aug 28, 16:00
23.74
-0.04
(-0.17%)
After-Hours: 20:00
Arcutis Biotherapeutics Cash from Operations (Quarterly) : 12.64M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.64M |
| March 31, 2026 | 2.239M |
| December 31, 2025 | 26.18M |
| September 30, 2025 | -1.754M |
| June 30, 2025 | 0.324M |
| March 31, 2025 | -30.38M |
| December 31, 2024 | -0.748M |
| September 30, 2024 | -34.69M |
| June 30, 2024 | -45.12M |
| March 31, 2024 | -31.60M |
| December 31, 2023 | -56.24M |
| September 30, 2023 | -43.98M |
| June 30, 2023 | -66.48M |
| March 31, 2023 | -80.34M |
| December 31, 2022 | -71.06M |
| September 30, 2022 | -67.70M |
| Date | Value |
|---|---|
| June 30, 2022 | -61.98M |
| March 31, 2022 | -56.98M |
| December 31, 2021 | -51.71M |
| September 30, 2021 | -40.88M |
| June 30, 2021 | -35.83M |
| March 31, 2021 | -46.20M |
| December 31, 2020 | -32.10M |
| September 30, 2020 | -34.16M |
| June 30, 2020 | -25.76M |
| March 31, 2020 | -21.01M |
| December 31, 2019 | -18.09M |
| September 30, 2019 | -10.92M |
| June 30, 2019 | -8.154M |
| March 31, 2019 | -7.074M |
| December 31, 2018 | -5.838M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Insmed, Inc. | -88.83M |
| Emergent BioSolutions, Inc. | 56.10M |
| Exelixis, Inc. | 307.74M |
| Vertex Pharmaceuticals, Inc. | 1.125B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -15.22M |
| Cash from Financing (Quarterly) | 1.99M |
| Free Cash Flow | 39.15M |
| Free Cash Flow Per Share (Quarterly) | 0.0918 |
| Free Cash Flow to Equity (Quarterly) | 13.02M |
| Free Cash Flow to Firm (Quarterly) | 15.86M |
| Free Cash Flow Yield | 1.23% |